Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Ashvattha Therapeutics

Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Accelerates Clinical Development Strategy with Leadership Appointment of Six Leading Retinal Specialists to Clinical Advisory Board
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha to Present at Upcoming Angiogenesis, Exudation, and Degeneration 2025 and BIO CEO Conferences
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Announces $50 Million Financing Extension and Interim Phase 2 Ophthalmology Trial Results
From Ashvattha Therapeutics
Via GlobeNewswire
Ashvattha Therapeutics Announces Two Oral Presentations at the World Molecular Imaging Congress 2021
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics Announces Participation at Upcoming Investor Conferences
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics Announces Positive Interim Data from Ongoing Phase 2 PRANA Clinical Study of OP-101 in Severe COVID-19 Patients
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum
From Ashvattha Therapeutics
Via Business Wire
Ashvattha Therapeutics Presents Transformative Anti-Angiogenesis Treatment for Retinal Disorders at ARVO 2021
From Ashvattha Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.